5Metis Revenue and Competitors

Location

$16M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • 5Metis's estimated annual revenue is currently $3.1M per year.(i)
  • 5Metis's estimated revenue per employee is $155,000
  • 5Metis's total funding is $16M.

Employee Data

  • 5Metis has 20 Employees.(i)
  • 5Metis grew their employee count by -5% last year.

5Metis's People

NameTitleEmail/Phone
1
CEO and Chief Scientific OfficerReveal Email/Phone
2
Director BiologyReveal Email/Phone
3
Greenhouse ManagerReveal Email/Phone
4
Regulatory Safety Program ManagerReveal Email/Phone
5
Greenhouse ManagerReveal Email/Phone
6
Research Scientist - Plant PathologyReveal Email/Phone
7
Lead Formulation ChemistReveal Email/Phone
8
COO at 5Metis Inc.Reveal Email/Phone
9
Research Associate-BiologyReveal Email/Phone
10
Senior Research FellowReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.9M777%N/AN/A
#2
$6221.7M40140-4%N/AN/A
#3
$2M130%N/AN/A
#4
$0.8M5-55%N/AN/A
#5
$2.8M186%$11.1MN/A
#6
$1M13-41%N/AN/A
#7
$1.7M110%N/AN/A
#8
$0.6M40%N/AN/A
#9
$5.9M38-5%N/AN/A
#10
$6.8M447%N/AN/A
Add Company

What Is 5Metis?

Welcome to 5Metis, Inc. 5Metis is a novel mode of action and intellectual property development company solving fungicide resistance for growers worldwide. Headquartered in Research Triangle Park, North Carolina, 5Metis was founded in 2021. Since its founding, 5Metis has discovered and validated multiple novel modes of action for agricultural fungicides.\n\nToday, 5Metis leverages its natural product screening and boron chemistry (NAB) platform to deliver novel modes of action not currently found in the agrichemical industry. As a result, 5Metis compounds break resistance to existing fungicides and can reduce application rates substantially. 5Metis is the only company with this unique intellectual property, exclusive boron chemistry library, and overall know-how to drive truly differentiated solutions.\n\nThe 5Metis business model focuses on discovery and early development and collaborates with channel partners for further development of de‐risked compounds with attractive biological profiles.\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less

keywords:N/A

$16M

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.8M20-17%N/A
#2
$3.1M2018%N/A
#3
$2M200%N/A
#4
$2M20N/AN/A
#5
$2.1M2018%N/A